Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Recovery & repair |
| Evidence grade | Emerging |
| Also known as | Thymosin Beta-4 fragment, TB4 |
| Mechanism | Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines. |
| Key benefits | Improved cell migration and wound closure in animal studies · Reported flexibility gains and reduced muscle spasm · Systemic action rather than site-specific, unlike BPC-157 |
| Side effects | Fatigue or head-rush after dosing · Injection-site reaction · Theoretical tumour-growth concern given angiogenic activity |
| Half-life | Roughly 2–3 hours, with tissue effects lasting far longer |
| Administration | Subcutaneous or intramuscular injection |
| Dosing overview | Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose |
| Storage | Powder at room temperature short term; reconstituted 2–8 °C for up to 30 days |
| Legal status | Not approved for human use; sold for research purposes only. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.